

## Lecture 22 Tissue Engineering




**Tissue Engineering:** a field that seeks to replace, repair or enhance biological function at the scale of a tissue or organ by manipulating cells via their extracellular environment

### Objectives:

1. Fulfill a biomechanical role (bone, cartilage)
2. Replace physiological function (liver, nerve)
3. Deliver secretory products (insulin)
4. A combination of the above

### 3 Main Approaches:


1. Extracorporeal/cell encapsulation (3)
2. *In vitro* synthesis (1-4)
3. *In vivo* synthesis (1-4)



## 1. Extracorporeal/Cell Encapsulation

### Method:

1. Encapsulate cells of interest in semipermeable membrane
2. Implant encapsulated device or connect *ex vivo*
3. Cells secrete product  $\Rightarrow$  therapy
4. Remove/disconnect device when therapy concluded



### Advantages:

- Natural therapeutic response from living cells
- Use of nonhost cells—immunoisolation

### Issues:

- Potential for undesirable immune response from adsorption of complement proteins (similar to blood filtration membranes)
- Potential for thrombosis formation  
(Anti-coagulants used during *ex vivo* treatment)
- Potential for rupture of implanted devices

*Applications Investigated:*

- Diabetes treatment\*
  - Chronic pain\*
  - Neurodegenerative diseases: ALS (Lou Gehrig's disease, neuromuscular), Parkinson's, Alzheimer's, Huntington's disease (progressive brain death)
  - Dwarfism
  - Anemia/Hemophilia
  - Macular degeneration (blindness)
  - Cancer
  - Liver Failure\*
- \* = clinical trials

**Device Examples****Encapsulated Islets (Islet Technology Inc., St Paul, MN)**

**CapCell:** implantable membrane-encapsulated islets for glucose regulation


**Cells:** insulin-producing islets

**Use:** long-term treatment of diabetes

**Device:** alginate-based membrane confines islets

**Treatment:** islets transplanted into patient's pancreas; patients' blood flows thru membrane; islets detect glucose level variations & respond through insulin production

**Status:** preclinical trials (islet transplantation in clinical trials)



**Arbios Systems, Inc.** (recently acquired from Circe Biomedical)

**HepatAssist System:** an extracorporeal, bioartificial liver support system

**Cells:** primary porcine hepatocytes (pig liver cells)

**Use:** temporary liver function for transplant candidates

**Device:** hollow fiber bioreactor, oxygenator, pump

**Treatment:** plasma circulated through bioreactor and  
recombined with blood cells

**Status:** Phase I trials completed

Figure removed for copyright reasons.

## 2. *In vitro* Synthesis

### Method:

1. Cells seeded *in vitro* on scaffold device
2. Cells maintained in culture to expand population & develop tissue organization (in static culture or bioreactors)
3. Device implanted once cell colony is established
4. Device degrades, scaffold replaced by remodeled tissue




Figure by MIT OCW.

### *Advantages:*

- Natural therapeutic response from living tissues
- Permanent therapy
- Allows control and quantification not easily obtained *in vivo*

### *Issues:*

- Cell sources
  - possibility of rejection
  - tumorigenicity—cell lines
- Full organ restoration challenges (e.g., skin)

### *Applications Investigated:*

- Vasculature (resorbable & nonresorbable)
- Liver tissue
- Nerve tissue
- Cartilage\*
- Cornea\*
- Bladder\*
- Skin\*
- Bone
- Ligament
- Tendon
- Muscle
- Heart valve
- Heart


Link to list of websites of tissue engineering companies:

[http://www.cs.cmu.edu/~webwatch/text\\_only\\_industry.html](http://www.cs.cmu.edu/~webwatch/text_only_industry.html)

### 3. *In vivo* synthesis

#### *Method:*

1. Implant porous scaffold device
2. Cellular ingrowth *in vivo*
3. Scaffold replaced by remodeled tissue



#### *Advantages:*

- Natural therapeutic response from living tissues
- Permanent therapy
- No cell source problems

Figure by MIT OCW.

#### *Issues:*

- Uncontrolled biological response to implanted scaffold

#### *Applications Investigated:*

- Vasculature
- Skin\*
- Bone\*
- Nerve
- Ligament
- Cartilage (Knee Meniscus)

## Scaffolds for Tissue Generation

Purpose: replace functions of extracellular matrix (ECM)


### ECM functions:

1. cell anchorage
2. cell orientation
3. cell growth
4. mechanical integrity to neo-tissue
5. tissue microenvironment
6. cell differentiation
7. sequester, store & present soluble regulatory proteins
8. blueprint for tissue organization (e.g., biomineralized tissue)

### ECM types:

**Basal Lamina (basement membrane):** directly underlying epithelial cells; contains laminin, collagen, fibronectin, vitronectin

**Stromal tissue (interstitial matrix):** provides structural integrity; contains matrix-secreting cells (fibroblasts, osteoblasts), collagen, elastin, fibrillin, fibronectin, vitronectin, GAGs, glycoproteins, regulatory proteins






### Resorbable Tissue Engineering Scaffolds:

1. **Collagen-matrix**  
e.g., artificial skin  
drawback: immunogenic
2. **Biodegradable polymers: PLA, PGA, PLGA**  
e.g., cartilage  
drawback: no adhesion sites (can build in RGD)
3. **Hydroxyapatite, Bioglass**  
e.g., bone regeneration  
drawback: brittle, low strength

### Processing of Tissue Engineering Devices

#### *A. Design Issues*

1. **Cell density**  
must be sufficiently high to enable tissue formation, deliver therapy
2. **Transport of nutrients/oxygen/waste**  
nutrients must reach cells within the scaffold/encapsulation device



Limiting distance from nutrients can be gauged from the *Thiele modulus*,  $S$  (dimensionless ratio of consumption to supply)

$$S = \frac{k\rho x^2}{DC_o}$$

$D$  = nutrient diffusivity in device ( $\text{cm}^2/\text{sec}$ )

$C_o$  = nutrient concentration at source ( $\text{mol}/\text{cm}^3$ )

$k$  = cell nutrient uptake rate constant ( $\text{mol}/\text{sec}/\text{cell}$ )

$x$  = distance from nutrient source (bloodstream) ( $\text{cm}$ )

$\rho$  = cell density in device ( $\text{cells}/\text{cm}^3$ )

$S \gg 1 \Rightarrow$  cells consume more than can be delivered

$S \ll 1 \Rightarrow$  supply greater than demand

$S = 1 \Rightarrow$  supply balances demand; use as limit estimate for device design

**A rule of thumb in designing tissue engineering devices:  $x_{max} = 500 \mu\text{m}$ .**

## 3. Mechanical support

- Critical problem for hard tissue scaffolds
- Influenced by
  - materials choices
  - processing (orientation of polymers & composites)

## 4. Tissue organization blueprint

Cell migration guidance

chemical & morphology effects (chemo/hapto/durotaxis)

Cell Patterning

microcontact printing, microlithography

Spatial Organization of Multiple Cell Types


- most organs of more than one cell type
- pattern based on different ligands, ligand densities, ligand affinities

## *B. Scaffold Fabrication*

**Objective:** Continuous, high-surface area scaffolds

### 1. Fabrics

- Woven/nonwoven fibers
- Mechanical interlocking ⇒ pliable, 3D matrix
- Porosity and pore size roughly controlled




## 2. Bonded fibers

- PGA fibers dipped in PLLA/CH<sub>2</sub>Cl<sub>2</sub> solution
- Heat treat fibers at  $T_{g,PGA} < T < T_{m,PLLA}$  to bond PGA to PGA
- Dissolve away PLLA
- Improved mechanical properties over fabrics; similar porosity


## 3. Freeze-dried Foams

- Polymer solution immersed in liquid N<sub>2</sub> ⇒ phase separation
- Frozen solvent sublimates leaving porous scaffold
- Pore size  $\sim \lambda$  of spinodal decomposition ⇒ controlled pore structure




## 4. Salt-leached Foams

- polymer solution mixed with uniform salt crystals
- Solvent evaporates leaving solid polymer/salt composite
- Immerse in H<sub>2</sub>O to leach out salt
- Controlled porosities up to 93% (< 2 mm thick)



## 5. 3D Printing


- Cast a bed of polymer powder (e.g., PLGA)
- "Print" micron-sized droplets of solvent at desired points (chloroform)
- Congealed powder solidifies as solvent evaporates
- Repeat process, building up 3D structure
- Shake out uncongealed powder
- Precisely structured micron-porous polymer or ceramic scaffolds



## C. Encapsulation Methods


### 1. Encapsulation Microspheres

- Cells attach to surface of polymer microspheres
- Cell-coated spheres suspended in weak polycation (polylysine  $-\text{NH}_3^+$ )
- Add polyanion (e.g. sodium alginate,  $-\text{COO}^-$ )
- Polyelectrolytes form precipitated, porous complex around cells (Complex coacervation)
- Single microbeads contain a few hundred cells (thousands needed for therapy)




2. Encapsulation Membranes

- Cast concentrated solution onto substrate (flat or tubular)
- Substrate immersed into a nonsolvent bath
- Coagulation of asymmetric membrane results




Microporous substructure  
(mechanical rigidity, high flux)

Dense surface layer (bath side)  
(semi-permeable)



- Cells suspended in gel within sealed membrane tube (length ~ 3 cm) or disk (dia ~ 2-3 cm)



➤ Membrane characteristics

- Molecular weight cutoff: typically ~30-70 kg/mol (<100 nm dia. pores)

Note: Ab ~150 kg/mol

<b>Molecule/Moiety</b>	<b>Size</b>
O <sub>2</sub> , H <sub>2</sub> O, salts	2-3 Å
Lipids, glucose	10 Å
Serum proteins, endotoxins	100 Å
Viruses	1000 Å
Bacteria	10 <sup>4</sup> Å
White blood cells, platelets	10 <sup>5</sup> Å

- Matrix examples: polysaccharides, alginate/chitosan coacervate, collagen
- Body: PAN-PVC, PP, polycarbonate, cellulose nitrate, acrylic
- Shape & Size: disks vs. tubes

	<b>Disks</b>	<b>Tubes</b>
<b>Mass transport</b>	Favored	diameter restrictions
<b>Susceptibility to clotting</b>	high surface area increases clot propensity	favored
<b>Cell #</b>	50-100M	5M

	<b>Cell # required</b>
<b>Diabetes</b>	$10^9$
<b>Clotting factor</b>	$10^7$ - $10^8$
<b>CNS therapies</b>	$10^6$ - $10^7$

***D. Current Challenges***

1. Micromechanical effects  
 Cell differentiation and growth (especially in load-bearing tissues) can be affected by micromechanical stresses transmitted by the scaffold
2. Cell function deterioration
3. Cross-application to other areas (gene therapy, drug delivery)
4. Multicellular tissues and organs
  - Complex, multicomponent structures (vascularized tissues)
  - Regeneration-inducing factors (proteins) only known for blood & bone



**Basic Tissue Cell Types and Functions**


Cell type	Tissue Function	Example
epithelial	covers external (ex, skin) & internal (ex, intestine, blood vessel) organ surfaces	endothelial cells
connective	supports other body tissues; houses nerves & blood vessels	fibroblasts (ECM generation), cartilage, bone
muscle	specialized for contraction;	smooth, skeletal, cardiac
nerve	generate electrical signals & secrete neurotransmitters	brain cells, peripheral nerve



Skin cell




Connective tissue cell



Muscle cell



Granule cell



Bone cell



Cartilage cell

**Cell Regeneration Capability**

<b>Category</b>	<b>Normal replic. rate</b>	<b>Response to injury</b>	<b>Examples</b>
renewing/ labile	High; via stem cell differentiation	modest ↑	skin, intestinal mucosa, bone marrow
Expanding/ stable	Low	large ↑	endothelium, fibroblasts, hepatocytes, osteoblasts
Static/ permanent	None	No replication; replaced by scar tissue	heart muscle cells, nerve cells